Favorable Press Coverage Somewhat Unlikely to Affect Bio-Rad Laboratories (NYSE:BIO) Share Price

Press coverage about Bio-Rad Laboratories (NYSE:BIO) has trended positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Rad Laboratories earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.0313388410746 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Bio-Rad Laboratories (NYSE BIO) traded down $2.84 during trading hours on Friday, reaching $248.37. The company had a trading volume of 176,339 shares, compared to its average volume of 182,267. Bio-Rad Laboratories has a 12 month low of $183.43 and a 12 month high of $273.87. The firm has a market cap of $7,476.76, a price-to-earnings ratio of 314.39, a P/E/G ratio of 2.03 and a beta of 0.97. The company has a quick ratio of 2.77, a current ratio of 4.06 and a debt-to-equity ratio of 0.15.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The company had revenue of $535.00 million for the quarter, compared to analyst estimates of $507.99 million. During the same period in the prior year, the company posted $0.62 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. equities analysts predict that Bio-Rad Laboratories will post 2.68 earnings per share for the current fiscal year.

Bio-Rad Laboratories declared that its Board of Directors has authorized a share repurchase plan on Tuesday, November 28th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

BIO has been the subject of a number of analyst reports. Zacks Investment Research upgraded Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. TheStreet upgraded Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research note on Monday, November 13th. Deutsche Bank restated a “buy” rating and set a $255.00 price objective on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and set a $290.00 target price (up from $250.00) on shares of Bio-Rad Laboratories in a research report on Wednesday, November 29th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $277.75.

In other news, CFO Christine A. Tsingos sold 4,980 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $249.40, for a total value of $1,242,012.00. Following the transaction, the chief financial officer now directly owns 7,283 shares of the company’s stock, valued at $1,816,380.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Giovanni Magni sold 2,400 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total value of $607,224.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $2,340,595.51. The disclosure for this sale can be found here. Insiders sold 9,126 shares of company stock worth $2,309,426 over the last three months. Corporate insiders own 28.29% of the company’s stock.

WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/bio-rad-laboratories-bio-receives-news-sentiment-score-of-0-25.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Insider Buying and Selling by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply